Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia

Background and Objectives: This analysis evaluated insomnia severity and long-term impact on healthcare resource utilization (HCRU) and costs after treatment with Somryst[R] (previously called SHUTi), a digital therapeutic delivering cognitive behavioral therapy for insomnia (CBT-I). Methods: Change...

Full description

Saved in:
Bibliographic Details
Published in:ClinicoEconomics and outcomes research 2022-01, Vol.14, p.537-546
Main Authors: Forma, Felicia, Knight, Tyler G, Thorndike, Frances P, Xiong, Xiaorui, Baik, Rebecca, Velez, Fulton F, Maricich, Yuri A, Malone, Daniel C
Format: Article
Language:English
Subjects:
Alzheimer's disease
Behavior
Behavioral health care
Care and treatment
Cognitive behavioral therapy
Cognitive therapy
COVID-19
Diaries
Evidence-based medicine
Health aspects
Health care
Health care expenditures
Insomnia
Medicaid
Medical care
Medicare
Original Research
Patients
Remission (Medicine)
Review boards
Sleep
Software
Surgical clinics
Utilization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objectives: This analysis evaluated insomnia severity and long-term impact on healthcare resource utilization (HCRU) and costs after treatment with Somryst[R] (previously called SHUTi), a digital therapeutic delivering cognitive behavioral therapy for insomnia (CBT-I). Methods: Change from baseline in insomnia severity index (ISI) score was assessed using last observed ISI score. A pre/post analysis of claims data was conducted, comparing HCRU in patients with self-identified sleep problems who successfully initiated the therapeutic (index date) between June 1, 2016 and December 31, 2018. Results: A total of 248 patients were analyzed (median age 56.5 years, 57.3% female, mean ISI score 19.13, 52.4% treated with sleep aid medications pre-index). After 9 weeks, mean ISI score declined by 37.2% from baseline (19.1 vs 12.0), 58.8% of patients achieved ISI responder status (ISI score improved by =>7; NNT: 1.7), and 26.6% of patients achieved insomnia remission (ISI score
ISSN:1178-6981
1178-6981
DOI:10.2147/CEOR.S368780